A pASHion for Painting: Charles S. Greenberg, MD
In this edition, Charles S. Greenberg, MD, shares his passion for painting and how it has helped to alleviate the stress physicians face. Dr. Greenberg is a hematologist at Medical University of South Carolina who focuses on classical hematologic diseases.
Freezing Stem Cells May Not Impair Overall Survival, Relapse After AlloHCT
BRAF Plus MEK Inhibition Efficacious in BRAF+ Multiple Myeloma
Matthew Matasar, MD
Dr. Matthew Matasar discusses the challenges of burnout in the field of hematology and proposes solutions to lessen its occurrence.
Decitabine Yields Similar Survival Despite Superior Responses Versus HU in MP-CMML
OCE Announces FOA for Ultra-Rare Cancer Research
Most Read Articles
Pulling Back the Curtain: Sarah O’Brien, MD
In this edition, Sarah O’Brien, MD, discusses why she chose the subspeciality of pediatric hematology, some of her passion projects, and the meaning of work-life integration. Dr. O’Brien is a pediatric hematologist at Nationwide Children’s Hospital, the Abigail Wexner investigator in the Center for Child Health Equity and Outcomes Research at Nationwide Children’s Research Institute, and associate professor of pediatrics at The Ohio State University College of Medicine.
Which Modality Is Preferred in Hemophilia: Factor or Non-Factor Prophylaxis?
In this edition of “Drawing First Blood,” Beth Warren, MD, and Alice Ma, MD, discuss the differences between factor and non-factor prophylaxis.
Glofitamab Shows Durable Remissions in R/R DLBCL
A phase II trial included 155 patients with DLBCL who had either relapsed after or been refractory to at least two previous therapies. Patients were given glofitamab at a starting dose of 2.5 mg on the first day of the first 21-day cycle, slowly increasing to the target dose over multiple cycles.